You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

CLINICAL TRIALS PROFILE FOR IV PERSANTINE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Iv Persantine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT02273531 ↗ Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers Completed Boehringer Ingelheim Phase 1 2004-01-01 Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox®)
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Iv Persantine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003018 ↗ S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer Completed National Cancer Institute (NCI) Phase 2 1997-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
NCT00003018 ↗ S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer Completed Southwest Oncology Group Phase 2 1997-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
NCT00763009 ↗ Persantine: Variation in Response Trial Terminated United States Department of Defense Phase 4 2002-09-01 The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.
NCT00763009 ↗ Persantine: Variation in Response Trial Terminated UConn Health Phase 4 2002-09-01 The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.
NCT00906035 ↗ The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD) Terminated Boehringer Ingelheim N/A 2002-09-01 This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs. We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow in the legs. Platelets are cells in the blood that have the ability to adhere to each other to form clots.
NCT00906035 ↗ The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD) Terminated University of Pennsylvania N/A 2002-09-01 This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs. We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow in the legs. Platelets are cells in the blood that have the ability to adhere to each other to form clots.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iv Persantine

Condition Name

Condition Name for Iv Persantine
Intervention Trials
Healthy 2
Coronary Artery Disease 2
Henoch-Schönlein Purpura Nephritis 1
HIV Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Iv Persantine
Intervention Trials
Myocardial Ischemia 2
Coronary Disease 2
Coronary Artery Disease 2
Hypertension, Portal 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Iv Persantine

Trials by Country

Trials by Country for Iv Persantine
Location Trials
United States 29
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Iv Persantine
Location Trials
Pennsylvania 2
Connecticut 2
Arizona 1
Alabama 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Iv Persantine

Clinical Trial Phase

Clinical Trial Phase for Iv Persantine
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
Phase 1/Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Iv Persantine
Clinical Trial Phase Trials
Completed 5
Terminated 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Iv Persantine

Sponsor Name

Sponsor Name for Iv Persantine
Sponsor Trials
Boehringer Ingelheim 3
National Cancer Institute (NCI) 1
Chengdu University of Traditional Chinese Medicine 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Iv Persantine
Sponsor Trials
Other 12
Industry 4
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for IV Persantine (Dipyridamole)

Introduction

IV Persantine, also known as dipyridamole, is a coronary vasodilator used primarily as an adjunct to thallium myocardial perfusion imaging. Here, we will delve into the clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Usage

Mechanism of Action

Dipyridamole works by inhibiting the uptake of adenosine into platelets, endothelial cells, and erythrocytes, leading to an increase in local adenosine concentrations. This action stimulates the platelet A2-receptor, inhibiting platelet aggregation and causing vasodilation[5].

Clinical Trials

In clinical trials involving 3911 patients, IV Persantine was used as an adjunct to thallium myocardial perfusion imaging. These trials highlighted the drug's efficacy but also revealed potential serious adverse events such as myocardial infarction, severe bronchospasm, and cardiac arrhythmias. Despite these risks, the trials demonstrated the clinical utility of IV Persantine in diagnostic imaging[1].

Dosage and Administration

The recommended dose of IV Persantine is 0.142 mg/kg/minute, infused over 4 minutes, with a total dose not exceeding 60 mg. The drug must be diluted in a compatible solution to avoid local irritation[1].

Market Analysis

Global Market for Anti-Thrombotic Drugs

The global market for anti-thrombotic drugs, which includes anti-platelet agents like dipyridamole, was significant in the early 2010s. In 2013, the global sales of anti-thrombotic drugs were approximately $23.5 billion, with anti-platelet drugs accounting for 40.4% of this market. However, the market share of traditional anti-platelet drugs like clopidogrel has declined since the expiration of its patent in 2012[2][3].

Specific Market for IV Persantine

While IV Persantine is not as widely used as oral anti-platelet agents, it maintains a niche in the market due to its specific use in diagnostic imaging. The market for IV Persantine is relatively stable but faces competition from newer anticoagulant and anti-platelet agents.

Market Projections

Shift to Newer Anticoagulants

The market for anticoagulant drugs is evolving with the introduction of direct thrombin inhibitors and direct coagulation factor Xa inhibitors. These newer drugs, such as dabigatran and rivaroxaban, have seen rapid growth and are expected to dominate the market in the coming years. This shift may impact the market share of traditional anti-platelet agents like dipyridamole[2][3].

Stability in Diagnostic Imaging

Despite the rise of newer anticoagulants, IV Persantine is likely to maintain its position in the diagnostic imaging sector. Its specific use as an adjunct to thallium myocardial perfusion imaging ensures a consistent demand, albeit in a niche market.

Challenges and Opportunities

Adverse Events and Safety Concerns

IV Persantine is associated with serious adverse events, including cardiac arrhythmias and severe bronchospasm. These risks must be carefully managed and weighed against the benefits of using the drug in diagnostic procedures[1].

Regulatory Environment

The regulatory environment plays a crucial role in the market dynamics of pharmaceuticals. Any changes in regulations or the introduction of new guidelines could impact the use and market share of IV Persantine.

Future Outlook

Technological Advancements

Advancements in diagnostic imaging technologies may reduce the reliance on IV Persantine or create new opportunities for its use. For instance, improvements in non-invasive imaging techniques could expand the applications of dipyridamole.

Market Competition

The anticoagulant and anti-platelet drug market is highly competitive, with new drugs entering the market regularly. IV Persantine will need to compete with these newer agents, which may offer better safety profiles or more convenient administration routes.

Key Takeaways

  • Clinical Utility: IV Persantine remains a valuable tool in diagnostic imaging, particularly for thallium myocardial perfusion imaging.
  • Market Stability: Despite market shifts towards newer anticoagulants, IV Persantine is expected to maintain its niche in the diagnostic imaging sector.
  • Safety Concerns: The drug's use must be carefully managed due to associated serious adverse events.
  • Regulatory and Technological Factors: Changes in regulations and technological advancements could influence the future market for IV Persantine.

FAQs

What is the primary use of IV Persantine?

IV Persantine is primarily used as an adjunct to thallium myocardial perfusion imaging.

What are the common adverse events associated with IV Persantine?

Common adverse events include chest pain, headache, dizziness, electrocardiographic abnormalities, and hypotension. Serious adverse events can include myocardial infarction, severe bronchospasm, and cardiac arrhythmias[1].

How does IV Persantine work?

IV Persantine inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, leading to an increase in local adenosine concentrations and subsequent vasodilation[5].

What is the recommended dosage for IV Persantine?

The recommended dose is 0.142 mg/kg/minute, infused over 4 minutes, with a total dose not exceeding 60 mg[1].

Is IV Persantine safe during pregnancy?

IV Persantine is classified under Pregnancy Category B, meaning it should be used during pregnancy only if clearly needed, as there are no adequate and well-controlled studies in pregnant women[1].

Sources

  1. RxList: Persantine IV (Dipyridamole): Side Effects, Uses, Dosage...
  2. Journal of Thoracic Disease: Recent progress and market analysis of anticoagulant drugs - Fan
  3. Journal of Thoracic Disease: Recent progress and market analysis of anticoagulant drugs - Fan
  4. Fortune Business Insights: Clinical Trials Market Size, Share, Industry Trends, Growth, 2032
  5. FDA: Persantine - accessdata.fda.gov

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.